Liposomal Amikacin Aerosol for Shorter MAC Lung Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Mycobacterium avium complex (MAC) lung infections are lengthy, often exceeding 18 months, and lack a patient-reported outcome measure of efficacy, with limited effectiveness due to poor lung tissue penetration and potential toxicity of existing antibiotics.
Innovation Solution
A method involving aerosolized amikacin encapsulated in liposomes composed of dipalmitoylphosphatidylcholine (DPPC) and cholesterol, administered via a nebulizer, combined with a macrolide antibiotic and ethambutol, for a duration of at least 6 months to improve respiratory symptoms and achieve MAC sputum culture conversion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If intravenous amikacin or intramuscular streptomycin are used to treat MAC lung disease, then treatment efficacy is improved, but ototoxicity, loss of balance, and impaired kidney function occur due to poor lung tissue penetration and poor uptake by alveolar macrophages
Solution Approach 1:
Liposomes serve as intermediary carriers that enable amikacin to be delivered directly to lung tissue and alveolar macrophages through inhalation, bypassing the need for intravenous or intramuscular administration. The liposomal encapsulation protects the antibiotic while facilitating its transport across biological barriers, thereby achieving effective lung tissue penetration without systemic exposure that causes ototoxicity and nephrotoxicity
Solution Approach 2:
The invention utilizes aerosolization technology to deliver liposomal amikacin directly to the lungs through inhalation. This pneumatic delivery system transforms the liquid pharmaceutical composition into an aerosol that can be efficiently inhaled and deposited in lung tissue, achieving high local concentrations of the antibiotic while minimizing systemic circulation and associated toxicities
2Reliability
If current multidrug antibiotic regimens are administered for 12 months beyond culture conversion, then MAC lung disease is treated, but treatment duration exceeds 18 months resulting in loss of time and reduced productivity
Solution Approach 1:
The invention changes the pharmacokinetic parameters of amikacin delivery by using liposomal encapsulation and inhalation administration. This results in sustained release and prolonged residence time of the antibiotic in lung tissue, achieving and maintaining therapeutic concentrations that accelerate culture conversion and enable shorter overall treatment duration compared to conventional regimens
3Reliability
If intravenous aminoglycoside use is increased to improve treatment outcomes, then bacterial infection is controlled, but poor penetration into lung tissue and poor uptake by alveolar macrophages limit effectiveness
Solution Approach 1:
Liposomes act as mediators that facilitate the transport of amikacin into lung tissue and alveolar macrophages. The liposomal structure enables the antibiotic to cross biological membranes and accumulate in target cells, achieving high intracellular concentrations that are not attainable with conventional intravenous administration
Solution Approach 2:
The liposomal shell provides a flexible, biocompatible carrier that can be inhaled as an aerosol and then fuse with or be taken up by alveolar macrophages. This thin film structure allows efficient delivery of the antibiotic into the target cells, achieving high concentrations within macrophages where the bacteria reside
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method significantly improves respiratory symptoms and achieves MAC sputum culture conversion within 3 to 12 months, as measured by patient-reported outcomes, providing a more effective treatment duration than existing regimens.
Implementation Method 1
administering to the lungs of the patient comprises aerosolizing the pharmaceutical composition via a nebulizer to provide an aerosolized pharmaceutical composition
Implementation Method 2
amikacin, or a pharmaceutically acceptable salt thereof, encapsulated in a plurality of liposomes
Data Source
AI summary
Provided is a method for treating a newly diagnosed and untreated MAC lung infection comprising administering to the lungs of a patient for an administration period of at least about 6 months, a pharmaceutical composition comprising amikacin, or a pharmaceutically acceptable salt thereof, The pharmaceutical composition is aerosolized via a nebulizer to provide an aerosolized pharmaceutical composition comprising a mixture of free amikacin, or a pharmaceutically acceptable salt thereof, and liposomal complexed amikacin, or a pharmaceutically acceptable salt thereof, and the aerosolized pharmaceutical composition is administered via the nebulizer to the lungs of the patient once daily in a single dosing session. The treating comprises improving a respiratory symptom score as defined by one or more patient reported outcomes, during or subsequent to the administration period.